Preimplantation Genetic Diagnosis Using Blastocyst Biopsy and Array CGH
Last updated on July 2021Recruitment
- Recruitment Status
- Suspended
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Infertility
- Recurrent Pregnancy Loss
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: Double (Participant, Outcomes Assessor)Primary Purpose: Screening
Participation Requirements
- Age
- Between 32 years and 42 years
- Gender
- Only males
Description
Patients will be randomized after fertilization, and will be dropped from the study if they produce 3 or less blastocysts on day 5. The Primary efficacy endpoint of comparing the study group with the control will be (I) implantation rates and (II) multiple pregnancies (twin or higher order) comparin...
Patients will be randomized after fertilization, and will be dropped from the study if they produce 3 or less blastocysts on day 5. The Primary efficacy endpoint of comparing the study group with the control will be (I) implantation rates and (II) multiple pregnancies (twin or higher order) comparing the first transfer. The study may be extended to evaluate secondary efficacy endpoints which will be miscarriage rate and take home baby rates comparing the two groups.
Tracking Information
- NCT #
- NCT01546350
- Collaborators
- Reprogenetics, Livingston, NJ
- Long Island IVF, Melville, NY
- Reproductive Associates of Illinois, Highland Park, IL
- Yale University
- McGill University
- BlueGnome, Cambridge, UK
- Southern California Reproductive Center, CA
- Investigators
- Study Director: Santiago Munne, PhD Reprogenetics
Get Well Soon